TRAF3IP2-AS1

Across TCGA pan-cancer cohorts, TRAF3IP2-AS1 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated TRAF3IP2-AS1 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TRAF3IP2-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAF3IP2-AS1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PAAD show a favorable association.

LIHC, LUAD, and PAAD are the cancer types where TRAF3IP2-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Quartile	All	0.407	0.614	<.001	76	view →
LUAD	OS	Median	II,III,IV	0.841	0.648	.002	51	view →
PAAD	OS	Quartile	All	0.692	0.322	<.001	47	view →
OV	DFS	Median	II,III,IV	0.125	0.190	.008	44	view →
UCS	DFS	Tertile	IV	0.996	0.361	.024	42	view →
ACC	DFS	Tertile	All	0.266	0.779	<.001	42	view →
LAML	DFS	Median	All	0.495	0.253	<.001	42	view →
KICH	OS	Tertile	All	0.643	1.000	.005	37	view →
LGG	OS	Quartile	All	0.924	0.799	<.001	36	view →
MESO	OS	Median	IV	0.252	0.748	.002	31	view →
UCEC	DFS	Median	All	0.785	0.886	<.001	28	view →
COAD	DFS	Quartile	All	0.383	0.608	.009	27	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

TRAF3IP2-AS1–LIHC (DFS)

Open the LIHC breakdown →